Biotechnology company enGene Holdings Inc (Nasdaq: ENGN) declared on Wednesday that it has reached its target enrollment of 100 patients for the pivotal cohort of the Phase 2 LEGEND trial evaluating detalimogene voraplasmid in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS).
An update from the pivotal cohort is expected in the fourth quarter of 2025, with a Biologics License Application submission now planned for the second half of 2026.
Detalimogene, developed with enGene's Dually Derivatized Oligochitosan (DDX) platform, is a non-viral gene therapy designed to trigger a localised anti-tumour immune response. The therapy has received Regenerative Medicine Advanced Therapy and Fast Track designations from the U.S. Food and Drug Administration.
The multi-cohort LEGEND trial is also enrolling patients across the USA, Canada, Europe and the Asia-Pacific region in additional cohorts, including BCG-naïve and BCG-exposed NMIBC patients with CIS, as well as those with papillary-only disease.
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001
Chance Pharma reports NMPA acceptance of NDA for investigational respiratory drug CXG87
Racura Oncology identifies mechanism of action for (E,E)-bisantrene
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
ZYUS Life Sciences receives second US pain management patent
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
Photocure study supports cost-effectiveness of blue light cystoscopy
Apotex receives Health Canada approval for a generic Ozempic equivalent
Specialised Therapeutics' chronic graft-versus-host disease therapy approved in Australia
Telix Pharmaceuticals' MAA for TLX101-Px (Pixlumi) accepted for European review